Hepatocellular carcinoma during hormonotherapy for prostatic cancer

Am J Clin Oncol. 1994 Oct;17(5):390-2. doi: 10.1097/00000421-199410000-00006.

Abstract

A case is reported of a poorly differentiated hepatocellular carcinoma that occurred in a 65-year-old patient who was on hormonotherapy for prostatic adenocarcinoma. The diagnosis of hepatocellular carcinoma was made 3 months after the initiation of a hormonal treatment with cyproterone acetate (for 1 month) and an LH-RH agonist. A cause and effect relationship between steroid hormones and hepatocellular carcinoma has been advocated in the literature. The occurrence of hepatic malignancy after a short hormonal therapy makes our case very unusual.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Hepatocellular / chemically induced*
  • Cyproterone Acetate / adverse effects
  • Humans
  • Liver Neoplasms / chemically induced*
  • Male
  • Neoplasms, Second Primary / chemically induced*
  • Prostatic Neoplasms / drug therapy*
  • Triptorelin Pamoate / adverse effects

Substances

  • Triptorelin Pamoate
  • Cyproterone Acetate